Survey of oral propolis effect in patients with type 2 diabetes

Survey of oral propolis effect on antioxidant status, lipid peroxidation, lipid profiles, Insulin resistance, blood glucose and glycosylated hemoglobin in patients with type 2 diabetes: A double-blind placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017041019669N4

Enrollment

Registered

2017-05-20

Start date

2017-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Control group: placebo weight flour supplementation, 1.5 gr daily, three capsoles for 2 months. Intervention 2: Intervention group: Propolis capsules, 1500 mg daily, three capsules of

Placebo

Treatment - Drugs

Control group: placebo weight flour supplementation, 1.5 gr daily, three capsoles for 2 months

Intervention group: Propolis capsules, 1500 mg daily, three capsules of 500 mg, for two months

Eligibility

Sex/Gender

All

Age

30 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: having the type 2 diabetes -voluntary consent for participation in the study Exclusion criteria: -use of multivitamin-mineral supplements at least 6month before the study -smoking, alcohol abuse -treatment with insulin -having the hepatic, renal failure, cardiovascular, celiac, gastrointestinal, rheumatic

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Insulin. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;HbA1c. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Lipid profile. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Added at 2017-10-28: Fructosamine. Timepoint: Added at 2017-10-28: Before intervention and 2 month after intervention. Method of measurement: Added at 2017-10-28: Eliza.	—

Measure

Time frame

Fasting Blood Sugar. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Insulin. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;HbA1c. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Lipid profile. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Added at 2017-10-28: Fructosamine. Timepoint: Added at 2017-10-28: Before intervention and 2 month after intervention. Method of measurement: Added at 2017-10-28: Eliza.

—

Secondary

Measure	Time frame
Antioxidant indices. Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Added at 2017-10-28: Inflammatory factors. Timepoint: Added at 2017-10-28: Before intervention and 2 month after intervention. Method of measurement: Added at 2017-10-28: Eliza.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hossein Khadem Haghighian

Qazvin University of Medical Sciences

khademnut@yahoo.com+98 28 3732 7650

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026